Sanofi (SNY) Projected to Post Quarterly Earnings on Thursday

Sanofi (NASDAQ:SNY) is projected to post its Q4 2025 results before the market opens on Thursday, January 29th. Analysts expect Sanofi to post earnings of $0.83 per share and revenue of $11.1756 billion for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, January 29, 2026 at 8:30 AM ET.

Sanofi (NASDAQ:SNY) last released its earnings results on Friday, October 24th. The company reported $2.91 earnings per share for the quarter, topping the consensus estimate of $1.60 by $1.31. Sanofi had a net margin of 21.96% and a return on equity of 12.70%. The business had revenue of $15.46 billion for the quarter, compared to the consensus estimate of $12.62 billion. During the same period last year, the firm posted $2.25 earnings per share. The firm’s quarterly revenue was down 7.5% compared to the same quarter last year. On average, analysts expect Sanofi to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Sanofi Stock Up 1.0%

SNY stock opened at $46.18 on Thursday. The company has a quick ratio of 0.30, a current ratio of 1.06 and a debt-to-equity ratio of 0.16. Sanofi has a 12-month low of $44.62 and a 12-month high of $60.12. The company has a 50 day moving average of $48.68 and a two-hundred day moving average of $48.78. The company has a market cap of $112.63 billion, a price-to-earnings ratio of 10.82, a PEG ratio of 1.33 and a beta of 0.45.

Wall Street Analyst Weigh In

SNY has been the subject of a number of research analyst reports. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Sanofi in a report on Monday, December 8th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Sanofi in a report on Friday, January 16th. Weiss Ratings restated a “hold (c)” rating on shares of Sanofi in a research report on Monday, December 29th. UBS Group reaffirmed a “neutral” rating on shares of Sanofi in a research note on Friday, January 16th. Finally, Jefferies Financial Group reissued a “buy” rating on shares of Sanofi in a research note on Monday, October 27th. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat, Sanofi has an average rating of “Moderate Buy” and an average target price of $62.67.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Measured Wealth Private Client Group LLC acquired a new stake in Sanofi in the 3rd quarter valued at $29,000. Palisade Asset Management LLC bought a new position in shares of Sanofi in the 3rd quarter valued at about $30,000. Sittner & Nelson LLC acquired a new stake in shares of Sanofi in the third quarter valued at about $47,000. WealthCollab LLC raised its holdings in Sanofi by 21.6% during the third quarter. WealthCollab LLC now owns 1,538 shares of the company’s stock worth $73,000 after acquiring an additional 273 shares in the last quarter. Finally, Brown Brothers Harriman & Co. boosted its position in Sanofi by 618.7% during the third quarter. Brown Brothers Harriman & Co. now owns 2,271 shares of the company’s stock valued at $107,000 after purchasing an additional 1,955 shares during the last quarter. 14.03% of the stock is currently owned by institutional investors.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.